Last reviewed · How we verify
NCT03294707
Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10
Phase 1 trial testing AG10 oral tablet in Amyloid Cardiomyopathy, Transthyretin-Related in 56 participants. Completed in 18 May 2018.
5 February 2018
Quick facts
| Lead sponsor | Eidos Therapeutics, a BridgeBio company |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 56 |
| Start date | 11 September 2017 |
| Primary completion | 5 February 2018 |
| Estimated completion | 18 May 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- AG10 oral tablet — full drug profile →
- Placebo Oral Tablet — full drug profile →
Conditions studied
- Amyloid Cardiomyopathy, Transthyretin-Related — all drugs for Amyloid Cardiomyopathy, Transthyretin-Related →
Sponsor
Eidos Therapeutics, a BridgeBio company — full company profile →
Who can join
Adults 18 to 55, any sex, with Amyloid Cardiomyopathy, Transthyretin-Related. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single center, prospective, randomized, placebo-controlled study of AG10 in healthy adult subjects
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03294707
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Amyloid Cardiomyopathy, Transthyretin-Related
Currently open trials in the same condition.
- NCT04988386 — Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants · Phase 3 · active not recruiting
Other Eidos Therapeutics, a BridgeBio company trials
Trials by the same sponsor.
- NCT04988386 — Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants · Phase 3 · active not recruiting
- NCT04769479 — A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects · Phase 1 · completed
- NCT04418024 — Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy · Phase 3 · withdrawn
- NCT03860935 — Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy · Phase 3 · completed
- NCT03458130 — Study of AG10 in Amyloid Cardiomyopathy · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03294707 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eidos Therapeutics, a BridgeBio company
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03294707.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing